Staff Profile

Roles

• Wellcome Trust Clinical Research Career Development Fellow, Translational and Clinical Research Institute, Newcastle University
• Honorary Consultant in Infectious Diseases, Newcastle upon Tyne Hospitals NHS Foundation Trust 

Previous Positions

• Faculty Fellowship, Institute of Cellular Medicine, Newcastle University, 2017-2018
• NIHR Academic Clinical Lecturer in Infectious Diseases, Newcastle University, 2014-2016
• Specialty Registrar in Infectious Diseases and G(I)M, Northern Deanery, 2013-2017
• Welcome Trust Research Training Fellowship for Clinicians, University of Oxford 2010-2013
• Phizackerley Senior Scholarship, Balliol College Oxford 2012-2013
• Clinical Research Fellow, University of Oxford, 2009-2010
• Specialty Registrar in Infectious Diseases and G(I)M, West of Scotland Deanery, 2007-2013

Qualifications

• BMed Sci (1st Class Hons.) University of Aberdeen, 2001
• MB ChB (Distinction) University of Aberdeen, 2003 (awarded Strachan Bursary prize and Dyce Davidson medal)
• MRCP (ID) Royal College of Physicians, 2006
• DPhil University of Oxford, 2014

Professional Responsibilities

• Clinical Lead, ID Research Team, Newcastle upon Tyne Hospitals NHS Foundation Trust
• Associate Editor, Frontiers in Immunology, Viral Immunology section
• Co-chair, BIA/RCP Coronavirus Therapeutics Advisory Group (CTAG), Immunomodulators subgroup
• Member, Adult Primary Immunodeficiency Bone Marrow Transplant MDT
• Member, Newcastle HLH MDT
• Sample access committee, Newcastle Academic Health Partners Bioresource
• Member, Joint Research Scientific Executive Committee
• Member, Genomics England Clinical Interpretation Partnership (GeCIP)
• Member: BIA, ESID, BMA, RCP, HIHASC
• Peer reviewer (NEJM, Lancet, BMJ, JID, MRC, ERC etc.)

Clinical interests

I am a practicing clinician, with regular clinics in adult infectious diseases and a joint clinic with colleagues in Immunology. My specialist interests include severe and/or high consequence viral disease,  immunodeficiency, and autoinflammatory disease.

Research Interests

Discovery research

Our research aims to define protective and deleterious mechanisms of innate antiviral immunity, in the anticipation that such knowledge may reveal new therapeutic opportunities in viral and inflammatory disease. The processes by which cells detect viral pathogens are reasonably well understood, however less is known about how the downstream response(s) contribute to disease outcome. In this respect, inborn errors of immunity provide a rich resource, teaching us unique lessons about the action and regulation of antiviral signalling in humans.

Type I interferons (IFN-I) are central to the innate response to virus infection. Previously, we have identified human inborn errors which either impair or enhance IFN-I receptor signalling, leading respectively to viral disease or sterile autoinflammation. Thus precise calibration of this response appears essential to host defence and immune homeostasis. 

We are interested in the cellular and molecular regulation of IFN-I signalling and how this contributes to antiviral defence in tissues. We employ cutting-edge techniques of disease modelling, combining CRISPR/Cas9 gene editing in human induced pluripotent stem cell systems with studies in model organisms. We work closely with Professor Sophie Hambleton's Primary Immunodeficiency Group: http://www.ncl.ac.uk/icm/people/profile/sophie.hambleton and a range of national and international collaborators.

Current projects

Building on a longstanding interest in antiviral responses of macrophages, a current focus is on microglia, the resident macrophages of the brain parenchyma, and the role these cells play in responding to neurotropic viruses and coordinating the brain's IFN network.

Another area of focus is how innate IFNs intersect in antiviral defence of the airway epithelium. 

Finally, we are interested in modelling sterile IFN-I mediated pathology using in vivo models of human disease entities known as type I interferonopathies. 

Recently, in response to the SARS-CoV-2 pandemic, we have embarked on a programme of basic and translational research to characterise immune responses to SARS-CoV-2, through involvement in the UK Coronavirus Immunology Consortium (UK-CIC) and the PITCH consortium.

Clinical ID Research

Working with partners in Newcastle upon Tyne Hospitals NHS Foundation Trust and the NIHR North East and North Cumbria Clinical Research Network, I lead the delivery of a diverse clinical research portfolio of phase I-III vaccine and interventional studies in Infectious Disease.    

Group Members

Dr Aidan Hanrath (aidan.hanrath@ncl.ac.uk) - Academic Clinical Fellow

Catherine Hatton (C.F.Hatton2@newcastle.ac.uk) - PhD student (MRC DiMEN funded)

Matthew Drummond (M.Drummond2@newcastle.ac.uk) - PhD student (Faculty Fellowship)

Dr Sophie Howarth (Sophie.Howarth@newcastle.ac.uk) - Academic Foundation Programme trainee

Jess Tyerman (Jess.Tyerman@newcastle.ac.uk) - Research Technician

Sophie McGorrigan (s.mcgorrigan@newcastle.ac.uk) - MRes student

Holly Rutherford - PhD student (MRC DiMEN funded, co-supervised with Dr Noemie Hamilton, Sheffield University)

Clinical Research Fellow

Dr Jeremy Nell (jeremy.nell@nhs.net)

Allumni

Dr Benjamin Thompson - formerly PhD student (MRC DiMEN funded), now postdoctoral research associate with Prof van Der Veen, Leiden University Medical Centre

Dr Zoe Kirkham (z.kirkham@newcastle.ac.uk) - formerly Academic Foundation Programme trainee, now Oncology Clinical Fellow, Marsden Cancer Centre, London

Linh Truong - former MRes student, now DPhil candidate, Oxford University

MRes Immunobiology (MMB8015) 

MRes Biomedical Research in Health and Disease Module (MMB8018)

I supervise MRes and PhD students, and welcome enquiries. 

At present we have an open opportunity for a fully-funded PhD studentship. This seeks to characterise the involvement of IFNs in innate antiviral defence of human airway epithelium:

https://www.findaphd.com/phds/project/phd-studentship-guarding-the-frontier-innate-interferons-in-epithelial-antiviral-defence/?p143976

• Gothe F, Hatton CF, Truong L, Klimova Z, Kanderova V, Fejtkova M, Grainger A, Bigley V, Perthen J, Mitra D, Janda A, Fronkova E, Maravicikova D, Hambleton S, Duncan CJA. A Novel Case of Homozygous Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency With Hemophagocytic Lymphohistiocytosis. Clinical Infectious Diseases 2022, 74(1), 136-139.
• Gothe F, Stremenova Spegarova J, Hatton CF, Griffin H, Sargent T, Cowley SA, James W, Roppelt A, Shcherbina A, Hauck F, Reyburn HT, Duncan CJA, Hambleton S. Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency. Journal of Allergy and Clinical Immunology 2022, Epub ahead of print.
• van der Velden FJS, Van Delft F, Owens S, Llevadias J, McKean M, Pulford L, Taha Y, Williamson G, Campbell-Hewson Q, Hambleton S, Payne RP, Duncan C, Johnston C, Spegarova J, Emonts M. Case report: severe acute pulmonary COVID-19 in a teenager post autologous hematopoietic stem cell transplant. Frontiers in Pediatrics 2022, 10, 809061.
• RECOVERY Collaborative Group, Inc. The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Hunter E, De Soyza A, Agbeko R, Baker K, Barr A, Cameron E, Campbell Hewson Q, Duncan C, Emonts M, Fenn A, Francis S, Glover Bengtsson J, Greenhalgh A, Hanrath A, Houghton K, Jerry D, Jones G, Kelly S, Lane N, Macfarlane J, McAlinden P, McCullagh I, McDonald S, Mohammed O, Obukofe R, Parker J, Patience A, Payne B, Price D, Razvi S, Robson S, Sanchez Gonzalez A, Stephenson E, Welton R, West S, Wong E, Yelnoorkar J. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 2022, 399(10325), 665-676.
• Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MBJ, Duncan CJA, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM, on behalf of the NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases 2022, (ePub ahead of Print).
• Vlachogiannis N, Baker K, Georgiopoulos G, Lazaridis C, Schim van der Loeff I, Hanrath A, Sopova K, Tual-Chalot S, Gatsiou A, Spyridopoulos I, Stamatelopoulos K, Duncan C, Stellos K. Clinical frailty, and not features of acute infection, is associated with late mortality in COVID-19: a retrospective cohort study. Journal of Cachexia, Sarcopenia and Muscle 2022, 13(3), 1502-1513.
• Jackson RM, Hatton CF, Spegarova JS, Georgiou M, J Collin, E Stephenson, B Verdon, IJ Haq, R Hussain, JM Coxhead, H-S Mudhar, B Wagner, M Hasoon, T Davey, P Rooney, A Khan, C Ward, M Brodlie, M Haniffa, S Hambleton, L Armstrong, F Figueiredo, Queen R, Duncan CJ, Lako M. Conjunctival epithelial cells resist productive SARS-CoV-2 infection. Stem Cell Reports 2022, 17(7), 1699-1713.
• Hung RKY, Binns-Roemer E, Booth JW, Hilton R, Harber M, Santana-Suarez B, Campbell L, Fox J, Ustianowski A, Cosgrove C, Burns JE, Clarke A, Price DA, Chadwick D, Onyango D, Hamzah L, Bramham K, Sabin CA, Winkler CA, Post FA, Booth J, Waters A, Hand J, Clarke C, Murphy S, Murphy M, Campbell M, Richardson C, Knott A, Weir G, Cleig R, Soviarova H, Barbour L, Adams T, Kennard V, Trevitt V, Jones R, Levy J, Schoolmeester A, Duro S, Rabuya M, Jordan D, Solano T, Uzu H, Williams K, Lwanga J, Reid-Amoruso LE, Gamlen H, Stocker RJ, Ryan F, Mahiouz K, Cheetham T, Williams C, Nori A, Thomas C, Venkateshwaran S, Doctor J, Berlanga A, Post F, McQueen L, Bhagwandin P, Barbini B, Wandolo E, Appleby T, Driver L, Parr S, Deng H, Barber J, Crowe A, Taylor C, Poulton M, Boateng V, Klein M-P, O'Brien C, Ohene-Adomako S, Buckingham C, Trotman D, Quinn K, Flanagan K, Sullivan V, Middleditch H, Samuel I, Hamlyn E, McDonald C, Canoso A, Agbasi E, Liskova M, Barber S, Samarawickrama A, Ottaway Z, Norcross C, Oliveira A, Minton J, Lamont G, Cross R, Saiyad G, Ahmed S, Ashworth R, Window N, Murira J, Phyu K, Lindergard G, Shaw J, Holland S, Fox C, Flaherty J, Bevan M-A, George V, Branch M, Lambert P, Craggs A, Pett S, Lukha H, Vora N, Fiorino M, Nunez MM, Sally D, Pool E, Matthews R, Price DA, Stothard T, Patel B, McVittie I, Kennedy C, Shwab U, Payne B, Duncan S, Dixon J, Schmid M, Evans A, Duncan C, Hunter E, Taha Y, Astill N, Winkler C, David V, Ainsworth J, Vincent R, Kegg S, Saad C, Skinner S, Azzoug H, Russell J, Moussaoui T, Mabonga E, Ward D, Francoise J, Larbi W, Mitchell S, Manning A, Russell V, Burns F, Ngwu N, Edwards J, Hemat N, Fernandez T, Ferro F, Ferreira J, Nightingale A, Oakes-Monger T, Matila D, Nogueira P, Mutagwanya V, Isitt CE, Webb H, Popoola J, Korley K, Mencias M, Ribeiro P, Ramkhelawn R, Lara SO, Sajijad S, Winston A, Shaw A, Petersen C, Ring K, Rosenvinge M, Moyo T, Odong F, Gantert K, Ibe T, Sabin C, Hill T. Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV. Kidney International Reports 2022, 7(4), 786-796.
• Hung RKY, Rosenberg K-L, David V, Binns-Roemer E, Booth JW, Hilton R, Fox J, Burns F, Ustianowski A, Cosgrove C, Hamzah L, Burns JE, Clarke A, Chadwick D, Price DA, Kegg S, Campbell L, Bramham K, Sabin CA, Post FA, Winkler CA, Waters A, Hand J, Clarke C, Murphy S, Murphy M, Campbell M, Richardson C, Knott A, Weir G, Cleig R, Soviarova H, Barbour L, Adams T, Kennard V, Trevitt V, Jones R, Levy J, Schoolmeester A, Duro S, Rabuya M, Jordan D, Solano T, Uzu H, Williams K, Lwanga J, Reid-Amoruso LE, Gamlen H, Stocker RJ, Ryan F, Mahiouz K, Cheetham T, Williams C, Nori A, Thomas C, Venkateshwaran S, Doctor J, Berlanga A, Santana-Suarez B, McQueen L, Bhagwandin P, Barbini B, Wandolo E, Appleby T, Driver L, Parr S, Deng H, Barber J, Crowe A, Taylor C, Poulton M, Boateng V, Klein M-P, O'Brien C, Ohene-Adomako S, Buckingham C, Trotman D, Quinn K, Flanagan K, Sullivan V, Middleditch H, Samuel I, Hamlyn E, McDonald C, Canoso A, Agbasi E, Liskova M, Barber S, Samarawickrama A, Ottaway Z, Norcross C, Oliveira A, Minton J, Lamont G, Cross R, Saiyad G, Ahmed S, Ashworth R, Window N, Murira J, Phyu K, Lindergard G, Shaw J, Holland S, Fox C, Flaherty J, Bevan M-A, George V, Branch M, Lambert P, Craggs A, Pett S, Lukha H, Vora N, Fiorino M, Nunez MM, Sally D, Pool E, Matthews R, Stothard T, Patel B, McVittie I, Kennedy C, Shwab U, Payne B, Duncan S, Dixon J, Schmid M, Evans A, Duncan C, Hunter E, Taha Y, Astill N, Ainsworth J, Vincent R, Saad C, Skinner S, Azzoug H, Russell J, Moussaoui T, Mabonga E, Ward D, Francoise J, Larbi W, Mitchell S, Manning A, Russell V, Harber M, Ngwu N, Edwards J, Hemat N, Fernandez T, Ferro F, Ferreira J, Nightingale A, Oakes-Monger T, Matila D, Nogueira P, Mutagwanya V, Isitt CE, Webb H, Popoola J, Korley K, Mencias M, Ribeiro P, Ramkhelawn R, Lara SO, Sajijad S, Winston A, Shaw A, Petersen C, Ring K, Rosenvinge M, Moyo T, Odong F, Gantert K, Ibe T, Onyango D, Hill T. GSTM1 Copy Number and Kidney Disease in People With HIV. Kidney International Reports 2022, Epub ahead of print.
• Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, England A, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Horsington BM, Lambe T, Lazarus R, Libri V, Lillie PJ, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, Vichos I, White R, Nguyen-Van-Tam JS, Snape MD. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet 2022, 399(10319), 36-49.
• Duncan CJA, Skouboe MK, Howarth S, Hollensen AK, Chen R, Borresen ML, Thompson BJ, Spegarova JS, Hatton CF, Staeger FF, Andersen MK, Whittaker J, Paludan SR, Jorgensen SE, Thomsen MK, Mikkelsen JG, Heilmann C, Buhas D, Orbo NF, Bay JT, Marquart HV, De la Morena MT, Klejka JA, Hirschfeld M, Bogwardt L, Forss I, Masmas T, Poulsen A, Noya F, Rouleau G, Hansen T, Zhou S, Abrechtsen A, Alizadehfar R, Allenspach EJ, Hambleton S, Mogensen TH. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. Journal of Experimental Medicine 2022, 219(6), e20212427.
• Lazarus R, Taucher C, Brown C, Corbic I, Danon L, Dubischar K, Duncan CJA, Eder-Lingelbach S, Faust SN, Green C, Gokani K, Hochreiter R, Wright JK, Kwon D, Middleditch A, Munro APS, Naker K, Penciu F, Price D, Querton B, Riaz T, Ross-Russell A, Sanchez-Gonzalez A, Wardle H, Warren S, Finn A. Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. Journal of Infection 2022, (ePub ahead of Print).
• Shankar S, Beckett J, Tipton T, Ogbe A, Kasanyinga M, Dold C, Lumley S, Dengu F, Rompianesi G, Elgilani F, Longet S, Deeks A, Payne RP, Duncan CJA, Richter A, de Silva TI, Turtle L, Bull K, Barnardo M, Friend PJ, Dunachie SJ, Hester J, Issa F, Barnes E, Carroll MW, Klenerman P. SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. Journal of the American Society of Nephrology : JASN 2022, 33(5), 883-887.
• Hung RKY, Binns-Roemer E, Booth JW, Hilton R, Fox J, Burns F, Harber M, Ustianowski A, Hamzah L, Burns JE, Clarke A, Price DA, Kegg S, Onyango D, Santana-Suarez B, Campbell L, Bramham K, Sharpe CC, Sabin CA, Winkler CA, Post FA, Booth J, Waters A, Hand J, Clarke C, Murphy S, Murphy M, Campbell M, Richardson C, Knott A, Weir G, Cleig R, Soviarova H, Barbour L, Adams T, Kennard V, Trevitt V, Jones R, Levy J, Schoolmeester A, Duro S, Rabuya M, Jordan D, Solano T, Uzu H, Williams K, Lwanga J, Reid-Amoruso LE, Gamlen H, Stocker RJ, Ryan F, Mahiouz K, Cheetham T, Williams C, Nori A, Thomas C, Venkateshwaran S, Doctor J, Berlanga A, Post F, McQueen L, Bhagwandin P, Barbini B, Wandolo E, Appleby T, Driver L, Parr S, Deng H, Barber J, Crowe A, Taylor C, Poulton M, Boateng V, Klein M-P, O'Brien C, Ohene-Adomako S, Buckingham C, Trotman D, Quinn K, Flanagan K, Sullivan V, Middleditch H, Samuel I, Hamlyn E, McDonald C, Canoso A, Agbasi E, Liskova M, Barber S, Samarawickrama A, Ottaway Z, Norcross C, Oliveira A, Minton J, Lamont G, Cross R, Saiyad G, Ahmed S, Ashworth R, Window N, Murira J, Phyu K, Lindergard G, Shaw J, Holland S, Fox C, Flaherty J, Bevan M-A, George V, Chadwick D, Branch M, Lambert P, Craggs A, Pett S, Lukha H, Vora N, Fiorino M, Nunez MM, Sally D, Pool E, Matthews R, Price DA, Stothard T, Patel B, McVittie I, Kennedy C, Shwab U, Payne B, Duncan S, Dixon J, Schmid M, Evans A, Duncan C, Hunter E, Taha Y, Astill N, Winkler C, David V, Ainsworth J, Vincent R, Saad C, Skinner S, Azzoug H, Russell J, Moussaoui T, Mabonga E, Ward D, Francoise J, Larbi W, Mitchell S, Manning A, Russell V, Ngwu N, Edwards J, Hemat N, Fernandez T, Ferro F, Ferreira J, Nightingale A, Oakes-Monger T, Matila D, Nogueira P, Mutagwanya V, Cosgrove C, Isitt CE, Webb H, Popoola J, Korley K, Mencias M, Ribeiro P, Ramkhelawn R, Lara SO, Sajijad S, Winston A, Shaw A, Petersen C, Ring K, Rosenvinge M, Moyo T, Odong F, Gantert K, Ibe T, Sabin C, Hill T. Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV. Kidney International Reports 2022, Epub ahead of print.
• Ferrada MA, Savic S, Collins JC, Alessi H, Gutierrez-Rodrigues F, Kumar DBU, Wilson L, Goodspeed W, Topilow JS, Paik JJ, Poulter JA, Kermani TA, Koster MJ, Warrington KJ, Cargo C, Tattersall RS, Duncan CJA, Cantor A, Hoffmann P, Payne EM, Bonnekoh H, Krause K, Cowen EW, Calvo KR, Patel BA, Ombrello AK, Kastner DL, Young NS, Werner A, Grayson PC, Beck DB. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 2022, Epub ahead of print.
• Baker KF, Hanrath AT, Schim van der Loeff I, Tee SA, Capstick R, Marchitelli G, Li A, Barr A, Eid A, Ahmed S, Bajwa D, Mohammed O, Alderson N, Lendrem C, Lendrem DW, COVID Control Group THE, COVID Clinical Group THE, Pareja-Cebrian L, Welch A, Field J, Payne BAI, Taha Y, Price DA, Gibbins C, Schmid ML, Hunter E, Duncan CJA. COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis. Medical Sciences 2021, 9(1), 6.
• Hatton CF, Botting RA, Duenas ME, Haq IJ, Verdon B, Thompson BJ, Spegarova JS, Gothe F, Stephenson E, Gardner AI, Murphy S, Scott J, Garnett JP, Carrie S, Powell J, Khan CMA, Huang L, Hussain R, Coxhead J, Davey T, Simpson AJ, Haniffa M, Hambleton S, Brodlie M, Ward C, Trost M, Reynolds G, Duncan CJA. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Nature Communications 2021, 12(1), 7092.
• Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, Clutterbuck EA, Collins AM, Cox T, Darton TC, Dold C, Douglas AD, Duncan CJA, Ewer KJ, Flaxman AL, Faust SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J, Hill HC, Jenkin D, Kerridge S, Lazarus R, Libri V, Lillie PJ, Ludden C, Marchevsky NG, Minassian AM, McGregor AC, Mujadidi YF, Phillips DJ, Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD, Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Williams CJ, Hill AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN, Pollard AJ. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet 2021, 397(10282), 1351-1362.
• Stamatelopoulos K, Georgiopoulos G, Baker KF, Tiseo G, Delialis D, Lazaridis C, Barbieri G, Masi S, Vlachogiannis NI, Sopova K, Mengozzi A, Ghiadoni L, Ajdini B, Ghiadoni L, van der Loeff IS, Vlachopoulos C, Dimopoulos MA, Falcone M, Stellos K, Duncan CJA, Tiseo G, Barbieri G, Masi S, Mengozzi A, Falcone M, Monzani F, Menichetti F, Virdis A, Forfori F, Rubia B, Pietro B, Francesco C, Alessandra DR, Giulia B, Fabio G, Paolo M, Marco M, Chiara P, Naria P, Alessandro C, Carrozzi L, Francesco C, Santini M, Alessandro C, Martina B, Matteo B, Elia N, Stefano S, Francesca R, Giovanna F, Maria S, De Marco S, Rachele A, Valeria C, Simone P, Luciano C, Chiara S, Valentina G, Uliana M, Baker KF, van der Loeff IS, Hanrath AT, Hanrath AT, Duncan CJA, Tee SA, Capstick R, Marchitelli G, Li A, Barr A, Eid A, Ahmed S, Bajwa D, Mohammed O. Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19. Scientific Reports 2021, 11(1), 20239.
• Duncan CJA, Randall RE, Hambleton S. Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity. Trends in Genetics 2021, 37(1), 46-58.
• Duncan CJA, Hambleton S. Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy. Journal of Clinical Immunology 2021, 41(7), 1446-1456.
• Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, Meardon N, Faustini S, Al-Taei S, Moore SC, Tipton T, Hering LM, Angyal A, Brown R, Nicols AR, Gillson N, Dobson SL, Amini A, Supasa P, Cross A, Bridges-Webb A, Reyes LS, Linder A, Sandhar G, Kilby JA, Tyerman JK, Altmann T, Hornsby H, Whitham R, Phillips E, Malone T, Hargreaves A, Shields A, Saei A, Foulkes S, Stafford L, Johnson S, Wootton DG, Conlon CP, Jeffery K, Matthews PC, Frater J, Deeks AS, Pollard AJ, Brown A, Rowland-Jones SL, Mongkolsapaya J, Barnes E, Hopkins S, Hall V, Dold C, Duncan CJA, Richter A, Carroll M, Screaton G, de Silva TI, Turtle L, Klenerman P, Dunachie S, Abuelgasim H, Adland E, Adlou S, Akther HD, Alhussni A, Ali M, Ansari MA, Arancibia-Carcamo CV, Bayley M, Brown H, Chalk J, Chand M, Chawla A, Chinnakannan S, Cutteridge J, de Lara C, Denly L, Diffey B, Dimitriadis S, Drake TM, Donnison T, Dupont M, Eyre D, Fairman A, Gardiner S, Gilbert-Jarmillo J, Goulder P, Hackstein C-P, Hambleton S, Haniffa M, Haworth J, Holmes J, Horner E, Jamsen A, Jones C, Kasanyinga M, Kelly S, Kirk R, Knight ML, Lawrie A, Lee L, Lett L, Lillie K, Lim N, Mehta H, Mentzer AJ, O'Donnell D, Ogbe A, Pace M, Payne BAI, Platt G, Poolan S, Provine N, Ramamurthy N, Robinson N, Romaniuk L, Rongkard P, Sampson OL, Simmons B, Spegarova JS, Stephenson E, Subramaniam K, Thaventhiran J, Thomas S, Travis S, Tucker S, Turton H, Watson A, Watson L, Weeks E, Wilson R, Wood S, Wright R, Xiao H, Zawia AAT. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 2021, 184(23), 5699-5714.e11.
• Freij BJ, Hanrath AT, Chen R, Hambleton S, Duncan CJA. Life-threatening influenza, hemophagocytic lymphohistiocytosis and probable vaccine strain varicella in a novel case of homozygous STAT2 deficiency. Frontiers in Immunology 2021, 11, 624415.
• Gothe F, Howarth S, Duncan CJ, Hambleton S. Monogenic susceptibility to live viral vaccines. Current Opinion in Immunology 2021, 72, 167-175.
• Baker KF, Hanrath AT, Schim van der Loeff I, Kay LJ, Back J, Duncan CJA. National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clinical Medicine 2021, (ePub ahead of Print).
• Taha Y, Wardle H, Evans AB, Hunter ER, Marr H, Osborne W, Bashton M, Smith D, Burton-Fanning S, Schmid ML, Duncan CJA. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Annals of Clinical Microbiology and Antimicrobials 2021, 20(1), 85.
• Breathnach AS, Duncan CJA, Bouzidi KE, Hanrath AT, Payne BAI, Randell PA, Habibi MS, Riley PA, Planche TD, Busby JS, Sudhanva M, Pallett SJC, Kelleher WP. Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. Journal of Infection 2021, 83(2), 237-279.
• Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. Journal of Infection 2021, epub ahead of print.
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group THE. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397(10269), 99-111.
• Hanrath AT, Schim van der Loeff I, Lendrem DW, Baker KF, Price DA, McDowall P, McDowall K, Cook S, Towns P, Schwab U, Evans A, Dixon J, Collins J, Burton-Fanning S, Saunders D, Harwood J, Samuel J, Schmid ML, Pareja-Cebrian L, Hunter E, Murphy E, Taha Y, Payne BAI, Duncan CJA. SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis. Frontiers in Medicine 2021, 8, 636160.
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group THE. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 2021, 397(10277), 881-891.
• Sayer JA, Mabillard H, Tedd H, Speight A, Duncan C, Price DA. Case Report: Renal potassium wasting in SARS-CoV-2 infection. F1000Research 2020, 9, 659.
• Holden B, Quinney A, Padfield S, Morton W, Coles S, Manley P, Wensley A, Hutchinson C, Lillie PJ, Duncan CJA, Schmid ML, Li A, Foster K, Anaraki S, Dabrera G, Zambon M, Hughes GJ, Gent M. COVID-19: Public Health management of the first two confirmed cases identified in the UK. Epidemiology and Infection 2020, 148, e194.
• Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, Khan E, Mehta P, Martin-Gutierrez L, Waddington KE, Robinson GA, Ribeiro Santos L, McLoughlin E, Snell A, Adeney C, Schim van der Loeff I, Baker KF, Duncan CJA, Hanrath AT, Lendrem BC, De Soyza A, Peng J, J'Bari H, Greenwood M, Hawkins E, Peckham H, Marks M, Rampling T, Luintel A, Williams B, Brown M, Singer M, West J, Jury EC, Collin M, Tattersall RS. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. The Lancet Rheumatology 2020, 2(10), e594-e602.
• Hunter E, Price DA, Murphy E, Schim van der Loeff I, Baker KF, Lendrem D, Lendrem C, Schmid ML, Pareja-Cebrian L, Welch A, Payne BAI, Duncan CJA. First experience of COVID-19 screening of health-care workers in England. The Lancet 2020, 395(10234), e77-e78.
• Lillie PJ, Samson A, Li A, Adams K, Capstick R, Barlow GD, Easom N, Hamilton E, Moss PJ, Evans A, Ivan M, PHE IT, Taha Y, Duncan CJA, Schmid ML, AHCID Network. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. Journal of Infection 2020, 80(5), 578-606.
• Hatton CF, Duncan CJA. Microglia Are Essential to Protective Antiviral Immunity: Lessons From Mouse Models of Viral Encephalitis. Frontiers in Immunology 2019, 10, 2656.
• Duncan CJA, Thompson BJ, Chen R, Rice GI, Gothe F, Young DF, Lovell SC, Shuttleworth VG, Brocklebank V, Corner B, Skelton AJ, Bondet V, Coxhead J, Duffy D, Fourrage C, Livingston JH, Pavaine J, Cheesman E, Bitetti S, Grainger A, Acres M, Innes BA, Mikulasova A, Sun R, Hussain H, Wright R, Wynn R, Zarhrate M, Zeef LAH, Wood K, Hughes SM, Harris CL, Engelhardt KE, Crow YJ, Randall RE, Kavanagh D, Hambleton S, Briggs TA. Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. Science Immunology 2019, 4(42), eaav7501.
• Ryan L, Heed A, Foster J, Valappil M, Schmid ML, Duncan CJA. Acute kidney injury (AKI) associated with intravenous aciclovir in adults: incidence and risk factors in clinical practice. International Journal of Infectious Disease 2018, 74, 97-99.
• Duncan CJA, Dinnigan E, Theobald R, Grainger A, Skelton AJ, Hussain R, Willet JDP, Swan DJ, Coxhead J, Thomas MF, Thomas J, Zamvar V, Slatter MA, Cant AJ, Engelhardt KR, Hambleton S. Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20). Annals of the Rheumatic Diseases 2018, 77(5), 783-786.
• Widdrington JD, Emmerson I, Cullinan M, Narayanan M, Klejnow E, Watson A, Ong ELC, Schmid ML, Price DA, Schwab U, Duncan CJA. Pyogenic Spondylodiscitis: Risk Factors for Adverse Clinical Outcome in Routine Clinical Practice. Medical Sciences 2018, 6(4), 96.
• Duncan CJA, Charlton F, Bower M, Price DA. The unholy trinity of human herpesvirus 8-associated malignancy in a person living with HIV-1. AIDS 2018, 32(3), 404–406.
• Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, Edwards NJ, Tarama C, Ouedraogo N, Ouedraogo M, NjieJobe J, Diarra A, Afolabi MO, Tiono AB, Yaro JB, Adetifa UJ, Hodgson SH, Anagnostou NA, Roberts R, Duncan CJ, Cortese R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampmann B, Imoukhuede EB, Sirima SB, Bojang K, Hill AV, Nebie I, Ewer KJ. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Molecular Therapy 2017, 25(2), 547-559.
• Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nebie I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima S. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy 2016, 24(8), 1470–1477.
• Duncan CJA, Mohamad SMB, Young DF, Skelton AJ, Leahy TR, Munday DC, Butler KM, Morfopoulou S, Brown JR, Hubank M, Connell J, Gavin PJ, McMahon C, Dempsey E, Lynch NE, Jacques TS, Valappil M, Cant AJ, Breuer J, Engelhardt KR, Randall RE, Hambleton S. Human IFNAR2 deficiency: lessons for antiviral immunity. Science Translational Medicine 2015, 7(307), 307ra154.
• Duncan C, Mohamad S, Young D, Skelton A, Leahy R, Munday D, Butler K, Morfopoulou S, Brown J, Hubank M, Connell J, Gavin P, McMahon C, Dempsey E, Lynch N, Jacques T, Valappil M, Cant A, Engelhardt K, Breuer J, Randall R, Hambleton S. Human IFNAR2 Deficiency: Lessons For Antiviral Immunity. In: UKPIN 2015 Meeting. 2015, Belfast, Northern Ireland: Wiley-Blackwell Publishing Ltd.
• Duncan CJA, Hambleton S. Varicella zoster virus immunity: A primer. Journal of Infection 2015, 71(Suppl. 1), S47-S53.
• Elias SC, Choudhary P, deCassan SC, Biswas S, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Hodgson SH, Duncan CJ, Hill AV, Draper SJ. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology 2014, 141(4), 628-644.
• Walker KM, Okitsu S, Porter DW, Duncan C, Amacker M, Pluschke G, Cavanagh DR, Hill AV, Todryk SM. Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships. Immunology 2014, 145(1), 71-81.
• Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, deCassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One 2014, 9(9), e107903.
• Duncan CJA, Schmid ML, Schwab U, Price DA, Ong E. Futility of CD4+ monitoring in HIV-1 patients with CD4+ cell count above 350 cells/[mu]l on suppressive antiretroviral therapy. AIDS 2014, 28(17), 2638-2639.
• Duncan CJ, Williams JP, Schiffner T, Gartner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. Journal of Virology 2014, 88(4), 2025-2034.
• Duncan CJA, Hambleton S. Host genetic factors in susceptibility to mycobacterial disease. Clinical Medicine 2014, 14(Suppl. 6), s17-s21.
• Dixon J, Duncan CJA. Importance of antimicrobial stewardship to the English National Health Service. Infection and Drug Resistance 2014, 7, 145-152.
• Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ. Macrophage Infection via Selective Capture of HIV-1-Infected CD4⁺ T Cells. Cell Host and Microbe 2014, 16(6), 711-721.
• Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Molecular Therapy 2014, 22(11), 1992-2003.